title: Single-dose safety, tolerability, and pharmacokinetics of the antibiotic GSK1322322, a novel peptide deformylase inhibitor.
abstract: GSK1322322 is a potent inhibitor of peptide deformylase, an essential bacterial enzyme required for protein maturation. GSK1322322 is active against community-acquired skin and respiratory tract pathogens, including methicillin-resistant Staphylococcus aureus, multidrug-resistant Streptococcus pneumoniae, and atypical pathogens. This phase I, randomized, double-blind, placebo-controlled, 2-part, single-dose, dose escalation study (first time in humans) evaluated the safety, tolerability, and pharmacokinetics of GSK1322322 (powder-in-bottle formulation) in healthy volunteers. In part A, dose escalation included GSK1322322 doses of 100, 200, 400, 800, and 1,500 mg under fasting conditions and 800 mg administered with a high-fat meal. In part B, higher doses of GSK1322322 (2,000, 3,000, and 4,000 mg) were evaluated under fasting conditions. Of the 39 volunteers enrolled in the study, 29 and 10 volunteers were treated with GSK1322322 and placebo, respectively. Upon single-dose administration, GSK1322322 was absorbed rapidly, with median times to maximum plasma concentration (T(max)) ranging from 0.5 to 1.0 h. The maximum observed plasma concentration (C(max)) and exposure (area under the concentration-time curve [AUC]) of GSK1322322 were greater than dose proportional between 100 and 1,500 mg and less than dose proportional between 1,500 and 4,000 mg. Administration of the drug with a high-fat meal reduced the rate of absorption (reduced C(max) and delayed T(max)) without affecting the extent of absorption (no effect on AUC). GSK1322322 was generally well tolerated, with all adverse events being mild to moderate in intensity during both parts of the study. The most frequently reported adverse event was headache. Data from this study support further evaluation of GSK1322322.
authors: GlaxoSmithKline, Research Triangle Park, North Carolina, USA. odin.j.naderer@gsk.com
authors: Odin J
authors: OJ
authors: Naderer
authors: Etienne
authors: E
authors: Dumont
authors: John
authors: J
authors: Zhu
authors: Milena
authors: M
authors: Kurtinecz
authors: Lori S
authors: LS
authors: Jones
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000581:Amidohydrolases / Q000037:antagonists & inhibitors*; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics*; D019540:Area Under Curve; D001682:Biological Availability; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics*; D004041:Dietary Fats / Q000008:administration & dosage; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005215:Fasting / Q000097:blood; D006261:Headache / Q000209:etiology; D006801:Humans; D006877:Hydroxamic Acids / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics*; D008875:Middle Aged
chemical_list: D000900:Anti-Bacterial Agents; D019086:Bridged Bicyclo Compounds, Heterocyclic; D004041:Dietary Fats; C583947:GSK1322322; D006877:Hydroxamic Acids; D000581:Amidohydrolases; C084507:peptide deformylase
references: Clin Infect Dis. 2010 Sep 15;51 Suppl 2:S176-82
references: 20731575
references: Curr Med Chem. 2005;12(14):1607-21
references: 16022661
references: J Clin Microbiol. 2011 Nov;49(11):3928-30
references: 21918031
references: Infect Dis Clin North Am. 2010 Sep;24(3):639-53
references: 20674796
references: Appl Microbiol Biotechnol. 2010 Dec;88(6):1261-7
references: 20865256
references: Eur J Clin Pharmacol. 2006 Jun;62(6):423-9
references: 16770646
references: Future Microbiol. 2012 Jan;7(1):73-89
references: 22191448
references: Antimicrob Agents Chemother. 2001 Apr;45(4):1058-64
references: 11257016